VIR: מקדם מחיר להכנסות Vir Bio

The P/S trajectory illustrates the market valuation of Vir Biotechnology, Inc. (VIR), with the current level standing at 6.80. Vir Biotechnology, Inc. (VIR) develops antiviral drugs against influenza and hepatitis B through strategic alliances with scientific foundations. Production and testing are outsourced to third-party contractors. High liquidity enables the development of new platforms while protecting shareholder capital from dilution.

For Vir Biotechnology, Inc. (VIR), which is adapting its portfolio following a decline in demand for antivirals, the P/S ratio serves as an indicator of the market value of every dollar of revenue generated. Analyzing the price-to-sales ratio allows for an assessment of capitalization relative to actual sales, filtering out temporary noise and confirming business resilience driven by a strong scientific core and significant liquidity reserves.